Evotec SE (EVT.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 09:43PM CEST
| Previous Close | 18.50 |
| Open | 18.96 |
| Bid | 0.00 x 400000 |
| Ask | 0.00 x 400000 |
| Day's Range | 18.76 - 19.00 |
| 52 Week Range | 14.85 - 24.45 |
| Volume | |
| Avg. Volume | 1,641 |
| Market Cap | 3.349B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.59 |
| Earnings Date | Nov 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.58 |
ACCESSWIREEvotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D Economy
LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT BIOTECH INNOVATORS THROUGH CRITICAL INFLECTION POINTSAGREEMENT LEVERAGES EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM TO ENABLE GREATER ACCESS TO INDUSTRY-GRADE CAPABILITIES AND ...
- ACCESSWIRE
Evotec and Novo Nordisk Launch LAB eN(2) to Accelerate Translation in Cardiometabolic Diseases
LAB eN² WILL INVOLVE INSTITUTIONS INCLUDING HARVARD UNIVERSITY, MASS GENERAL BRIGHAM, AND BETH ISRAEL DEACONESS MEDICAL CENTERFOCUS OF THE COLLABORATION IS TO ACCELERATE THE TRANSLATION OF ACADEMIC IDEAS TO THERAPEUTIC PRODUCT CANDIDATES IN THE CARDIOMETABOLIC ...
- ACCESSWIRE
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced its financial results and corporate updates for the first half-year of 2023.
© 2023 Yahoo. All rights reserved.
